Needham analyst Alan Carr maintained a Buy rating on Moderna Inc (MRNA) today and set a price target of $28. The company’s shares closed last Monday at $15.73.
According to TipRanks.com, Carr is a 3-star analyst with an average return of 0.6% and a 41.4% success rate. Carr covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co Ltd, ACADIA Pharmaceuticals Inc, and Rhythm Pharmaceuticals Inc.
Moderna Inc has an analyst consensus of Strong Buy, with a price target consensus of $28.
See today’s analyst top recommended stocks >>
Based on Moderna Inc’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $135 million. In comparison, last year the company had a GAAP net loss of $37.94 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics.
